Antidepressants and drug-metabolizing enzymes ? expert group report
- 1 February 1996
- journal article
- review article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 93 (2) , 71-79
- https://doi.org/10.1111/j.1600-0447.1996.tb09805.x
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoinClinical Pharmacology & Therapeutics, 1992
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplificationThe Lancet, 1990
- Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.Proceedings of the National Academy of Sciences, 1988
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Extremely Rapid Hydroxylation of DebrisoquineTherapeutic Drug Monitoring, 1985
- Defective N-oxidation of sparteine in man: A new pharmacogenetic defectEuropean Journal of Clinical Pharmacology, 1979
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Relationship between Plasma Level and Therapeutic Effect of NortriptylineBMJ, 1971
- Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapyBMJ, 1969